EA201491531A1 - C-3 циклоалкенил тритерпеноиды, ингибирующие созревание вич - Google Patents

C-3 циклоалкенил тритерпеноиды, ингибирующие созревание вич

Info

Publication number
EA201491531A1
EA201491531A1 EA201491531A EA201491531A EA201491531A1 EA 201491531 A1 EA201491531 A1 EA 201491531A1 EA 201491531 A EA201491531 A EA 201491531A EA 201491531 A EA201491531 A EA 201491531A EA 201491531 A1 EA201491531 A1 EA 201491531A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cycloalkenyl
compounds
hiv maturation
inhibiting hiv
triterpenoids
Prior art date
Application number
EA201491531A
Other languages
English (en)
Other versions
EA024361B1 (ru
Inventor
Джейкоб Свидорски
Николас А. Минвелл
Алисия Регуейро-Рен
Син-Юэнь Сит
Цзи Чэнь
Янь Чэнь
Original Assignee
Бристол-Майерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48946098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201491531(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бристол-Майерс Сквибб Компани filed Critical Бристол-Майерс Сквибб Компани
Publication of EA201491531A1 publication Critical patent/EA201491531A1/ru
Publication of EA024361B1 publication Critical patent/EA024361B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Описаны соединения, имеющие лекарственную и биологическую активность, их фармацевтические композиции и способы их применения. В частности, предусмотрены С-3 циклоалкенил тритерпеноиды, которые обладают уникальной противовирусной активностью в качестве ингибиторов созревания ВИЧ, представленные соединениями формул I, II, III и IVгде X может представлять собой Cциклоалкил, Cциклоалкенил, Сспироциклоалкил, Сспироциклоалкенил, Cоксациклоалкил, Сдиоксациклоалкил, Cоксациклоалкенил, Cдиоксациклоалкенил, Cциклодиалкенил, Cоксациклодиалкенил, Cоксаспироциклоалкил и Cоксаспироциклоалкенил. Указанные соединения полезны для лечения ВИЧ и СПИД.
EA201491531A 2012-02-15 2013-02-13 C-3 циклоалкенил тритерпеноиды, ингибирующие созревание вич EA024361B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261599040P 2012-02-15 2012-02-15
US13/760,726 US8906889B2 (en) 2012-02-15 2013-02-06 C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
PCT/US2013/025897 WO2013123019A1 (en) 2012-02-15 2013-02-13 C-3 cycloalkenyl triterpenoids with hiv maturation inhibitory activity

Publications (2)

Publication Number Publication Date
EA201491531A1 true EA201491531A1 (ru) 2014-11-28
EA024361B1 EA024361B1 (ru) 2016-09-30

Family

ID=48946098

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491531A EA024361B1 (ru) 2012-02-15 2013-02-13 C-3 циклоалкенил тритерпеноиды, ингибирующие созревание вич

Country Status (26)

Country Link
US (1) US8906889B2 (ru)
EP (1) EP2814834B1 (ru)
JP (1) JP6155285B2 (ru)
KR (1) KR20140123584A (ru)
CN (2) CN104220451B (ru)
AR (1) AR089996A1 (ru)
AU (1) AU2013221725B2 (ru)
BR (1) BR112014019672A8 (ru)
CA (1) CA2864656A1 (ru)
CL (1) CL2014002141A1 (ru)
CO (1) CO7061077A2 (ru)
EA (1) EA024361B1 (ru)
ES (1) ES2656984T3 (ru)
HK (1) HK1204608A1 (ru)
IL (1) IL234077A (ru)
MX (1) MX2014009235A (ru)
MY (1) MY166793A (ru)
NZ (1) NZ631408A (ru)
PE (1) PE20142315A1 (ru)
PH (1) PH12014501816A1 (ru)
PT (1) PT2814834T (ru)
SG (1) SG11201404748XA (ru)
TW (1) TW201336863A (ru)
UY (1) UY34627A (ru)
WO (1) WO2013123019A1 (ru)
ZA (1) ZA201406724B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
EP2953960A1 (en) 2013-02-06 2015-12-16 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity
CA2944778C (en) 2014-04-11 2022-06-14 ViiV Healthcare UK (No.4) Limited Triterpenoids with hiv maturation inhibitory activity
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
AU2015346314B2 (en) * 2014-11-14 2018-04-12 VIIV Healthcare UK (No.5) Limited Extended betulinic acid analogs
US9969767B2 (en) 2014-11-14 2018-05-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
KR20170092581A (ko) 2014-11-14 2017-08-11 비브 헬스케어 유케이 (넘버5) 리미티드 Ｃ１７-아릴 치환된 베툴린산 유사체
AU2016248235A1 (en) * 2015-04-14 2017-10-19 Viiv Healthcare Uk (No 4) Limited Crystalline forms of modified triterpenoid hydrochloride salts with HIV maturation inhibitor activity
KR20180028534A (ko) * 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
CN108026139A (zh) 2015-07-28 2018-05-11 葛兰素史克知识产权第二有限公司 用于预防或治疗hiv感染的白桦脂醇衍生物
KR20180054826A (ko) 2015-09-24 2018-05-24 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 성숙 억제 활성을 갖는 화합물
EP3405474A1 (en) * 2016-01-20 2018-11-28 Glaxosmithkline Intellectual Property (No. 2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
CN106905264B (zh) * 2017-04-12 2019-06-07 连云港杰瑞药业有限公司 一种合成阿扎拉韦中间体的方法
KR20200052925A (ko) * 2017-09-13 2020-05-15 엠욘 인코퍼레이티드 우르솔산 모르폴린 및 디에탄올아민 염
EP4321164A3 (en) 2018-04-24 2024-04-17 ViiV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
CN109705189B (zh) * 2018-12-29 2020-06-05 中国医学科学院药用植物研究所 具有式i所示结构的三萜衍生物及其制备方法和应用
EA202192111A1 (ru) 2019-02-11 2022-01-26 Хетеро Лабс Лимитед Новые тритерпеновые производные в качестве ингибиторов вич
WO2020229398A1 (de) 2019-05-14 2020-11-19 Bayer Aktiengesellschaft (1-alkenyl)-substituierte pyrazole und triazole als schädlingsbekämpfungsmittel

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20050239748A1 (en) 2004-03-17 2005-10-27 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
EP2178376A4 (en) 2007-08-03 2011-12-14 Advanced Life Sciences Inc LUPANIC TRITERPENOIDS MODIFIED IN 30-POSITION AND ITS ANALOG
CA2711424A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
JP2011511812A (ja) * 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規１７βルパン誘導体
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
SG181803A1 (en) 2009-12-17 2012-07-30 Merck Sharp & Dohme Aminopyrimidines as syk inhibitors
US8802661B2 (en) 2010-06-04 2014-08-12 Bristol-Myers Squibb Company C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors
CA2801487C (en) * 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
CA2826113C (en) * 2011-01-31 2018-09-04 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
RS54352B1 (en) 2011-01-31 2016-02-29 Bristol-Myers Squibb Company C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV INVESTIGATION INHIBITORS
KR20140069167A (ko) * 2011-09-21 2014-06-09 브리스톨-마이어스 스큅 컴퍼니 항바이러스 활성을 갖는 신규 베툴린산 유도체
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
EP2953960A1 (en) * 2013-02-06 2015-12-16 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity

Also Published As

Publication number Publication date
WO2013123019A1 (en) 2013-08-22
AR089996A1 (es) 2014-10-01
HK1204608A1 (en) 2015-11-27
US8906889B2 (en) 2014-12-09
PT2814834T (pt) 2017-12-06
NZ631408A (en) 2015-06-26
BR112014019672A2 (ru) 2017-06-20
SG11201404748XA (en) 2014-09-26
EP2814834B1 (en) 2017-09-13
BR112014019672A8 (pt) 2017-07-11
EP2814834A1 (en) 2014-12-24
MX2014009235A (es) 2014-11-10
CN106046106A (zh) 2016-10-26
UY34627A (es) 2013-09-02
CA2864656A1 (en) 2013-08-22
AU2013221725A1 (en) 2014-10-02
CN104220451B (zh) 2016-06-29
JP6155285B2 (ja) 2017-06-28
IL234077A (en) 2016-11-30
US20130210787A1 (en) 2013-08-15
EA024361B1 (ru) 2016-09-30
AU2013221725B2 (en) 2016-10-27
TW201336863A (zh) 2013-09-16
CN104220451A (zh) 2014-12-17
JP2015510515A (ja) 2015-04-09
KR20140123584A (ko) 2014-10-22
MY166793A (en) 2018-07-23
ES2656984T3 (es) 2018-03-01
CL2014002141A1 (es) 2014-10-03
PE20142315A1 (es) 2015-01-16
IL234077A0 (en) 2014-09-30
PH12014501816A1 (en) 2014-11-17
CO7061077A2 (es) 2014-09-19
ZA201406724B (en) 2016-08-31

Similar Documents

Publication Publication Date Title
EA201491531A1 (ru) C-3 циклоалкенил тритерпеноиды, ингибирующие созревание вич
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201492016A1 (ru) C-17 бициклические амины тритерпеноидов с ингибиторной активностью созревания вич
EA201270800A1 (ru) С-28 амиды модифицированных производных с-3 бетулиновой кислоты в качестве ингибиторов созревания вич
EA201270780A1 (ru) С-3 модифицированные производные бетулиновой кислоты в качестве ингибиторов созревания вич
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201591545A1 (ru) C-3 алкил- и алкенил-модифицированные производные бетулиновой кислоты
UA111770C2 (uk) Інгібітори бромдомену
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
JO3357B1 (ar) مركبات إيميدازوبيروليدينون
EA201391098A1 (ru) C-28-амины c-3-модифицированных производных бетулиновой кислоты в качестве ингибиторов созревания вич
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
EA201492092A1 (ru) Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1
MX336381B (es) Boronatos como inhibidores de arginasa.
MX343534B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
UA113541C2 (xx) Заміщені піролідин-2-карбоксаміди
EA201692003A1 (ru) Макроциклические производные пиримидина
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
EA201692000A1 (ru) Макроциклические производные пиридина
EA201491013A1 (ru) Пиразиновые ингибиторы киназы
MX2014002936A (es) Nuevos derivados de acido betulinico con actividad antiviral.
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
MX363270B (es) Composiciones y metodos para inhibir la polimerasa viral.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU